🔎 Trials Near Me

홈 › 버킷 림프종 › 아이오와

아이오와의 버킷 림프종 임상 시험

버킷 림프종 관련 연구 7개가 아이오와 내 여러 지역에서 참여자를 모집하고 있습니다.

아이오와의 도시

공식 연구 텍스트(영어)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Blank Children's Hospital, Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06124157

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City
피험자 모집 중1/2상
6 Months – 25 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06395103

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중3상
18세 ~ 39세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Blank Children's Hospital, Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Blank Children's Hospital, Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center, Iowa City
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Iowa City
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT07109219

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.